Hedgehog Pathway Inhibitors Against Tumor Microenvironment

The document discusses the role of Hedgehog pathway inhibitors in targeting the tumor microenvironment in cancers such as medulloblastoma, breast cancer, and pancreatic cancer. It highlights the importance of the Hedgehog signaling pathway in cancer progression and the potential of inhibitors to disrupt this pathway, thereby impeding tumor growth and improving therapeutic outcomes. Evidence from multiple studies indicates that targeting the Hedgehog pathway can induce autophagy, apoptosis, and reduce chemoresistance in cancer cells. The FDA approval of Vismodegib for basal cell carcinoma underscores the clinical relevance of Hedgehog pathway inhibitors.